Mesa Laboratories Beheer
Beheer criteriumcontroles 2/4
De CEO Mesa Laboratories is Gary Owens, benoemd in Sep2017, heeft een ambtstermijn van 7.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.44M, bestaande uit 13.9% salaris en 86.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.8% van de aandelen van het bedrijf, ter waarde $ 4.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 4.5 jaar.
Belangrijke informatie
Gary Owens
Algemeen directeur
US$5.4m
Totale compensatie
Percentage CEO-salaris | 13.9% |
Dienstverband CEO | 7.2yrs |
Eigendom CEO | 0.8% |
Management gemiddelde ambtstermijn | 7.2yrs |
Gemiddelde ambtstermijn bestuur | 4.5yrs |
Recente managementupdates
Recent updates
Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding
Nov 20We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt
Oct 17A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb
Jul 29Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?
May 03Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?
Dec 05Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Aug 09We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking
May 31A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Apr 12Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Dec 20Mesa Laboratories declares $0.16 dividend
Oct 03Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Sep 09Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?
Sep 06Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M
Aug 04Mesa Laboratories declares $0.16 dividend
Jul 07Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$246m |
Jun 30 2024 | n/a | n/a | -US$250m |
Mar 31 2024 | US$5m | US$754k | -US$254m |
Dec 31 2023 | n/a | n/a | US$948k |
Sep 30 2023 | n/a | n/a | -US$717k |
Jun 30 2023 | n/a | n/a | US$2m |
Mar 31 2023 | US$5m | US$733k | US$930k |
Dec 31 2022 | n/a | n/a | -US$1m |
Sep 30 2022 | n/a | n/a | -US$4m |
Jun 30 2022 | n/a | n/a | -US$2m |
Mar 31 2022 | US$18m | US$579k | US$2m |
Dec 31 2021 | n/a | n/a | US$8m |
Sep 30 2021 | n/a | n/a | US$5m |
Jun 30 2021 | n/a | n/a | US$4m |
Mar 31 2021 | US$3m | US$524k | US$3m |
Dec 31 2020 | n/a | n/a | -US$2m |
Sep 30 2020 | n/a | n/a | -US$2m |
Jun 30 2020 | n/a | n/a | -US$2m |
Mar 31 2020 | US$3m | US$600k | US$2m |
Dec 31 2019 | n/a | n/a | US$5m |
Sep 30 2019 | n/a | n/a | US$10m |
Jun 30 2019 | n/a | n/a | US$8m |
Mar 31 2019 | US$3m | US$520k | US$7m |
Dec 31 2018 | n/a | n/a | US$10m |
Sep 30 2018 | n/a | n/a | -US$2m |
Jun 30 2018 | n/a | n/a | -US$249k |
Mar 31 2018 | US$1m | US$417k | -US$3m |
Compensatie versus markt: De totale vergoeding ($USD 5.44M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).
Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.
CEO
Gary Owens (56 yo)
7.2yrs
Tenure
US$5,435,566
Compensatie
Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 7.2yrs | US$5.44m | 0.80% $ 4.3m | |
VP, CFO & Chief Accounting Officer | 12.1yrs | US$1.94m | 0.22% $ 1.2m | |
Senior Vice President of Continuous Improvement | 6.8yrs | US$1.62m | 0% $ 0 |
7.2yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MLAB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 7.2yrs | US$5.44m | 0.80% $ 4.3m | |
Lead Independent Director | 3.1yrs | US$220.03k | 0.057% $ 303.1k | |
Independent Chairman of the Board | 15.7yrs | US$255.13k | 1.34% $ 7.2m | |
Independent Director | 2.4yrs | US$220.13k | 0.049% $ 264.1k | |
Independent Director | less than a year | US$90.03k | 0.013% $ 71.4k | |
Independent Director | 4.5yrs | US$220.13k | 0.051% $ 274.6k | |
Independent Director | 5.7yrs | US$220.13k | 0.064% $ 342.5k |
4.5yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).